Skip to content
10-Q

Quarterly Report

INHIBIKASE THERAPEUTICS, INC. IKT

0001193125-25-283169

← back to feed
Filed
Nov 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 7, 2025 75.18M sh
Shares Diluted Q3 2025 · Sep 30, 2025 90.05M sh
Shares Diluted Q3 2025 · Sep 30, 2025 89.87M sh
Shares Diluted Q3 2025 · Sep 30, 2024 8.88M sh
Shares Diluted Q3 2025 · Sep 30, 2024 7.59M sh
Capex Q3 2025 · Sep 30, 2025 $13.4K
Capex Q3 2025 · Sep 30, 2024 $0
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$20.27M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$13.8M
Stockholders Equity Q3 2025 · Sep 30, 2025 $72.9M
Stockholders Equity Q3 2025 · Jun 30, 2025 $80.05M
Stockholders Equity Q3 2025 · Mar 31, 2025 $85.73M
Stockholders Equity Q3 2025 · Dec 31, 2024 $94.87M
Stockholders Equity Q3 2025 · Sep 30, 2024 −$530.59K
Stockholders Equity Q3 2025 · Jun 30, 2024 $5.1M
Stockholders Equity Q3 2025 · Mar 31, 2024 $6.78M
Stockholders Equity Q3 2025 · Dec 31, 2023 $10.98M
Current Liabilities Q3 2025 · Sep 30, 2025 $6.7M
Current Liabilities Q3 2025 · Dec 31, 2024 $3.73M
Total Liabilities Q3 2025 · Sep 30, 2025 $6.7M
Total Liabilities Q3 2025 · Dec 31, 2024 $3.73M
Current Assets Q3 2025 · Sep 30, 2025 $78.54M
Current Assets Q3 2025 · Dec 31, 2024 $98.45M
Total Assets Q3 2025 · Sep 30, 2025 $79.59M
Total Assets Q3 2025 · Dec 31, 2024 $98.6M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.13
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.40
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.65
Eps Diluted Q3 2025 · Sep 30, 2024 −$2.03
Eps Basic Q3 2025 · Sep 30, 2025 −$0.13
Eps Basic Q3 2025 · Sep 30, 2025 −$0.40
Eps Basic Q3 2025 · Sep 30, 2024 −$0.65
Eps Basic Q3 2025 · Sep 30, 2024 −$2.03
Sga Expense Q3 2025 · Sep 30, 2025 $5.61M
Sga Expense Q3 2025 · Sep 30, 2025 $16.78M
Sga Expense Q3 2025 · Sep 30, 2024 $1.64M
Sga Expense Q3 2025 · Sep 30, 2024 $5.64M
Rd Expense Q3 2025 · Sep 30, 2025 $7.65M
Rd Expense Q3 2025 · Sep 30, 2025 $23.43M
Rd Expense Q3 2025 · Sep 30, 2024 $4.19M
Rd Expense Q3 2025 · Sep 30, 2024 $10.02M
Net Income Q3 2025 · Sep 30, 2025 −$11.93M
Net Income Q3 2025 · Sep 30, 2025 −$35.52M
Net Income Q3 2025 · Jun 30, 2025 −$9.92M
Net Income Q3 2025 · Mar 31, 2025 −$13.68M
Net Income Q3 2025 · Sep 30, 2024 −$5.78M
Net Income Q3 2025 · Sep 30, 2024 −$15.39M
Net Income Q3 2025 · Jun 30, 2024 −$4.96M
Net Income Q3 2025 · Mar 31, 2024 −$4.65M
Operating Income Q3 2025 · Sep 30, 2025 −$12.77M
Operating Income Q3 2025 · Sep 30, 2025 −$38.2M
Operating Income Q3 2025 · Sep 30, 2024 −$5.83M
Operating Income Q3 2025 · Sep 30, 2024 −$15.66M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2024 $0
Revenue Q3 2025 · Sep 30, 2024 $0